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Eong-length stenting has a poor outcome when bare
etal stents are used. The safety and efficacy of the
irolimus-eluting stent (SES) in long lesions has not been
valuated. Therefore, the aim of the present study was
o evaluate the clinical and angiographic outcomes of
ES implantation over a very long coronary artery seg-
ent. Since April 2002, all patients treated percutane-
usly at our institution received a SES as the device of
hoice as part of the Rapamycin Eluting Stent Evaluated
t Rotterdam Cardiology Hospital (RESEARCH) registry.
uring the RESEARCH registry, stents were available in
engths of 8, 18, and 33 mm. The present report includes
predefined study population consisting of patients
reated with >36-mm-long stented segments. Patients
ad a combination of >2 overlapping stents at a mini-
um length of 41 mm (i.e., one 33-mm SES overlapping
n 8-mm SES) to treat native de novo coronary lesions.
he incidence of major cardiac adverse events (death,I
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The American Journal of Cardiology Vol. 93 April 1, 2004onfatal myocardial infarction, and target lesion revas-
ularization) was evaluated. The study group comprised
6 consecutive patients (102 lesions). Clinical follow-up
as available for all patients at a mean of 320 days
range 265 to 442). In all, 20% of long-stented lesions
ere chronic total occlusions, and mean stented length
er lesion was 61.2  21.4 mm (range 41 to 134).
ngiographic follow-up at 6 months was obtained in 67
atients (71%). Binary restenosis rate was 11.9% and
n-stent late loss was 0.13  0.47 mm. At long-term
ollow-up (mean 320 days), there were 2 deaths (2.1%),
nd the overall incidence of major cardiac events was
.3%. Thus, SES implantation appears safe and effective
or de novo coronary lesions requiring multiple stent
lacement over a very long vessel segment. 2004 by
xcerpta Medica, Inc.
(Am J Cardiol 2004;93:826–829)reatment of complex coronary artery stenosis with
a long segment of bare metal stent is associated
ith high restenosis rates and poorer clinical out-
ome.1–7 Therefore, in contrast to shorter lesions, stent
lacement for diffusely diseased coronary segments is
requently avoided. The efficacy of the sirolimus-
luting stent (SES) implantation has been recently
valuated in the context of 2 large randomized trials.
he RAndomized study with the sirolimus-eluting Bx
Elocity balloon-expandable stent in the treatment of
atients with de novo native coronary artery Lesions
RAVEL) trial8 included only single lesions covered
y an 18-mm-long stent and had a zero restenosis rate.
rom the Department of Interventional Cardiology, Thoraxcentre, Eras-
us MC, Rotterdam, The Netherlands. This study was supported in
art by health care funds allotted by the Erasmus Medical Center,
otterdam, The Netherlands, and by an institutional grant from Cordis,
ohnson & Johnson, Miami Lakes, Florida. Manuscript received
ctober 8, 2003; revised manuscript received and accepted
ecember 4, 2003.
Address for reprints: Patrick W. Serruys, MD, PhD, Department of
nterventional Cardiology, Erasmus MC Rotterdam, Thoraxcentre Bd
04, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
-mail: p.w.j.c.serruys@erasmusmc.nl.n the US Multicenter, Randomized, Double-Blind
tudy of the SIRolImUS-eluting Bx velocity balloon
xpandable stent (SIRIUS) trial,9 relatively long stent
lacement was allowed (maximum of 2 overlapping
8-mm-long SESs) and the restenosis rate was 9.2%.
he efficacy of a SES implanted over a total coronary
ength 36 mm has not been tested to date. In the
resent study, we sought to evaluate the outcomes of
atients receiving overlapping stents implanted over a
ength 36 mm to treat native de novo coronary
esions.
ETHODS
Since April 16, 2002, it has been our policy to use
he SES (Cypher, Cordis Europa NV, Roden, The
etherlands) as the device of choice for every percu-
aneous coronary intervention performed at our
nstitution as part of the Rapamycin Eluting Stent
valuated At Rotterdam Cardiology Hospital (RE-
EARCH) registry. Further details of the methods
ave been previously described.10
Study group and stent implantation: During the
ESEARCH registry enrollement, SESs were avail-
ble at lengths of 8, 18, and 33 mm. The present report
ncludes a predefined study group composed of pa-
0002-9149/04/$–see front matter
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bients treated with stented segments 36 mm long.
herefore, because of the availability of stent lengths,
ll included patients had a combination of at least 2
verlapping stents at a minimum length of 41 mm
i.e., one 33-mm SES overlapping an 8-mm SES).
atients receiving a SES to treat in-stent restenotic
esions were excluded from the present analysis. Also,
esions with angiographically visible gaps between
tents were not included in this study. During 6
onths of enrollment, 96 consecutive patients (102
esions) fulfilled the above criteria and formed the
resent study group. The stented length was based on
he cumulative length of the patient’s adjacent stents.
ll procedures were performed according to standard
nterventional techniques, except with the use of the
ES as the device of choice. However, the final inter-
entional strategy was entirely left at the discretion of
he operator (angiographic success defined as 30%
esidual diameter stenosis by visual assessment in the
resence of Thrombolysis In Myocardial Infarction
TIMI-3) trial anterograde flow). All patients received
ifelong aspirin and clopidogrel 75 mg/day for 6
onths. Glycoprotein IIb/IIIa inhibitors were given at
he discretion of the physician. The hospital ethics
ommittee approved the study protocol and written
nformed consent was obtained from all patients.
Definitions and follow-up: All patients were evalu-
ted for the occurrence of major cardiac adverse
vents, defined as death, myocardial infarction, target
esion revascularization, and target vessel revascular-
zation. In-hospital outcome information was retrieved
y means of an electronic clinical database for patients
aintained in our hospital after the procedure and by
eview of the hospital records for those discharged to
econdary hospitals. After discharge, recordings of all
epeat interventions (surgical and percutaneous) and
ehospitalizations were prospectively collected in a
edicated database. Follow-up information was ob-
TABLE 1 Baseline Patient Demographics and Procedural Data
Patients with Lon
(n  96,
Age (yrs) 64
Men 6
Diabetes 1
Current smoking 2
Hypercholesterolemia 5
Hypertension 4
Previous myocardial infarction 3
Previous balloon angioplasty 1
Target vessel
Left anterior descending artery 4
Left circumflex artery
Right coronary artery 4
Chronic total occlusion 2
Direct stenting 5
Multivessel disease 5
Primary percutaneous coronary intervention
Glycoprotein IIb/IIIa inhibitor use 3
Mean no. of sirolimus-eluting stents per lesion 2.66  0.9
Mean length of sirolimus-eluting stent per lesion (mm) 61.2  21.4
Mean diameter of Sirolimus-eluting stent (mm) 2.82ained by regular outpatient evaluation, by phone con- m
CORONARY ARTERY DISEASE/Ctact, or by mail. Myocardial infarc-
tion was documented by an increase
in the creatine kinase level of more
than twice the upper limit, with an
increased creatine kinase-MB. Car-
diac markers were measured serially
for all patients maintained in our in-
stitution. Among those discharged to
their community hospitals, cardiac
markers were collected only if a
postprocedural myocardial infarction
was suspected. Consequently, enzy-
matic assessment was not available
for all patients, but for those whom
the likelihood of postprocedure myo-
cardial infarction was high.10 Target
vessel revascularization was defined
as either surgical or percutaneous re-
intervention driven by significant
(50%) luminal narrowing either
within the stent or within the 5-mm
borders proximal and distal to the
stent, and was undertaken in the
resence of either anginal symptoms or objective ev-
dence of ischemia. All living patients at 6 months
ere considered eligible for angiographic follow-up.
inary restenosis was defined as diameter stenosis
50% within the stent or in the 5-mm segments
roximal or distal to the stent. Late loss was defined as
he difference between the minimal luminal diameter
mmediately after the procedure and at follow-up.
Statistical analysis: Discrete variables are presented
s counts and percentages. Continuous variables are
resented as mean  SD and compared by Student’s
test.
ESULTS
Baseline and procedural characteristics of the 96
atients (102 lesions) are listed in Table 1. Approxi-
ately half of lesions were located in the left anterior
escending coronary artery (47%) or in the right cor-
nary artery (44%). The mean number of stents per
esion was 2.66  0.9 (range 2 to 6 stents), and the
verage stented length was 61.2  21.4 mm. The
ngiographic success rate was 97%. Follow-up coro-
ary angiography was performed in 67 patients (71%
f eligible cases) (Table 2). Binary restenosis (diam-
ter stenosis 50%) was identified in 8 lesions
11.9%). Among the 8 lesions (8 patients) with binary
estenosis, 5 occurred within the stent, 1 in the prox-
mal segment, and 2 in the distal 5-mm adjacent vessel
egment. All post-SES restenoses were focal and 10
m in length. Among these 8 patients, 4 were asymp-
omatic and did not undergo repeat revascularization.
omplete clinical follow-up was available for all pa-
ients at an average of 320  67.4 days (range 265 to
42) and is summarized in Table 3.
Two patients died. One patient died during the
n-hospital period after emergent bypass surgery for a
rocedure related to left main stem dissection caused
y the guiding catheter. The second patient was ad-
Stented Segment
lesions)
12
nge 2–6)
nge 41–134)
0.24ger
102

2%
8%
6%
7%
5%
2%
9%
7%
9%
4%
0%
3%
2.1%
8%
1%
(ra
(ra
itted in cardiogenic shock due to postinfarction un-
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8table angina. He had 3-vessel disease, but the treat-
ent was restricted to the culprit lesion. In total, six
.25-mm diameter SESs were implanted in the left
nterior artery/diagonal bifurcation. The patient died
uddenly 43 days after the procedure. Although there
s no clear evidence, subacute stent thrombosis cannot
e ruled out in this case. Nonfatal myocardial infarc-
ion occurred in 1 patient. He developed a no-reflow
henomenon after stent placement, which was re-
olved after intracoronary adenosine and nitropruside
nfusion. At 6 months follow-up angiography, the
atient was asymptomatic with a patent long-stented
egment.
Two patients underwent emergent bypass surgery
or left main dissection. One patient died in the hos-
ital as previously mentioned, and the other had been
uccessfully treated for left main dissection, but de-
eloped cardiac tamponade after the procedure and
nderwent surgical pericardial drainage, during which
e received a venous graft to the first obtuse marginal
ranch.
In all, 4 patients were successfully treated with
epeat percutaneous coronary intervention electively
or focal restenotic lesions. Overall, major adverse
ardiac event-free survival was 91.7% at 320-day fol-
ow-up.
ISCUSSION
We report that the use of long length of SES
mplantation for de novo coronary lesions is associ-
ted with a low rate of major adverse cardiac events,
ainly because of a reduced incidence of target lesion
evascularization. In particular, SES demonstrated ef-
TABLE 2 Quantitative Coronary Angiography Analysis After Pro
Postprocedure Proximal 5 mm
Vessel reference diameter (mm) 3.17  0.55
Minimal lumen diameter (mm) 2.76  0.54
% diameter stenosis 12
6-mo follow-up
Vessel reference diameter (mm) 3.30  0.61
Minimal lumen diameter (mm) 2.74  0.58
% diameter stenosis 17
Late lumen loss (mm) 0.02  0.52
TABLE 3 Major Adverse Cardiac Events (n  96) at 320
Days of Follow-up
Death 2 (2.1%)
Nonfatal myocardial infarction 1 (1.0%)*
Target vessel revascularization 6 (6.2%)
Target lesion revascularization 4 (4.2%)
CABG 2 (2.1%)†
Any major adverse cardiac event 8 (8.3%)
*Non–Q-wave myocardial infarction peak creatine kinase 567IU (MB frac-
tion 62IU).
†One of 2 patients who underwent emergency coronary artery bypass graft
surgery for left main stem dissection died in the hospital.
CABG  coronary artery bypass graft surgery.ective suppression of neointimal hyperplasia with a c
28 THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 93ate lumen loss of 0.13 mm, which is substantially
ower than that of major published studies with bare
etal stents for long segments, ranging from 0.79 to
.41 mm.1,3–5 Accordingly, the restenosis rate ob-
erved after SES was strikingly lower. Importantly,
he average stented length in our study was at least 10
m longer than in previous series with bare metal
tents.
Longer stented segment length using bare metal
tents is an independent predictor of restenosis and
dverse events.1 Long stenting is frequently associated
ith prolonged intracoronary manipulation due to
ultiple and overlapping stent placement, which may
ead to injury to the vessel wall integrity. Moreover,
he greater metal density may be potentially associated
ith a higher degree of local vascular injury, which
ltogether may increase the risk of cardiac events and
estenosis. The incidence of late complications has
een reported to be directly proportional to the total
ength of stents implanted. Previously, Schalij et al6
eported a 25% incidence of major adverse events for
atients treated with bare metal stents at a mean
tented length of 45 mm. In the Additional Value of
IR Stents for Treatment of Long Coronary Lesions
ADVANCE)3 Study, the reported major adverse car-
iac event rate was 23%. The present results are
eassuring, because the relatively low incidence of
dverse events (8.3%) presented in our series occurred
n association with a markedly long length of the
mplanted SES (61 mm on average).
Among 5 patients (7.4%) with in-stent restenosis,
nly 1 focal in-stent restenosis was seen in the over-
apped stented segment. Furthermore, consistent with
revious reports regarding the angiographic pattern of
estenosis of SES,11 all our restenoses were focal and
herefore easy to treat with repeat percutaneous coro-
ary intervention. Because all patients with angio-
raphically visible gaps between stents were excluded
rom the present analysis, incomplete lesion coverage
as not identified as a possible mechanism of reste-
osis in any case.
There have been concerns that the risk for throm-
osis may increase after implantation of the long
ength of the stent. In the present study, no docu-
ented thrombotic stent occlusion was observed, al-
hough we cannot rule out stent thrombosis in the
atient who died suddenly 43 days after the index
rocedure. There is no consensus for the period of
ure and Data at Six-month Follow-up (n  67)
In-stent Distal 5 mm
2.68  0.51 2.45  0.51
2.17  0.47 1.94  0.53
18 20
2.82  0.59 2.63  0.62
2.04  0.64 2.12  0.60
27 19
0.13  0.47 0.16  0.47cedlopidogrel prescription after SES implantation, espe-
APRIL 1, 2004
c
l
u
m
e
t
s
c
o
a
c
e
d
o
r
g
w
r
P
r
t
t
w
t
1
D
r
2
G
o
C
3
v
o
c
o
3
4
R
a
t
5
d
c
r
C
6
B
r
I
7
M
c
s
8
C
r
c
9
C
S
c
1
A
e
f
(
1
A
sially after treatment of complex lesions. Although no
ate thrombotic events were diagnosed after discontin-
ation of clopidogrel in our series (i.e., after 6
onths), additional studies are warranted to further
valuate the best antiplatelet scheme for these pa-
ients.
Several limitations are noteworthy because of the
mall cohort of patients without a direct comparative
ontrol group. Angiographic follow-up could not be
btained in all patients. Nonetheless, not consenting to
ngiographic follow-up was not considered as an ex-
lusion criterion for the RESEARCH study, which
nrolled all unselected, consecutive patients treated in
aily practice with percutaneous interventions. Obvi-
usly, this scenario differs substantially from that of
andomized trials and limits the compliance to angio-
raphic restudy. However, all eligible patients for
hom angiographic re-evaluation was not obtained
emained event free throughout the follow-up period.
ostprocedure cardiac markers were not collective
outinely for all patients (available for 46 of 96 pa-
ients [46%] in the study group). This was justified by
he fact that high-grade enzymatic elevations (those
ith proved prognostic impact) rarely occur undetec-
ed in asymptomatic patients.
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